Business
Glenmark Pharmaceuticals Limited Press Release Mar 04 2026
Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated March 04, 2026, titled "Glenmark Specialty SA Receives U.S. FDA Approval for Fluticasone Propionate Inhalation Aerosol USP, 44 mcg per actuation, with 180-Day Competitive Generic Therapy Exclusivity".
About this update from Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated March 04, 2026, titled "Glenmark Specialty SA Receives U.S. FDA Approval for Fluticasone Propionate Inhalation Aerosol USP, 44 mcg per actuation, with 180-Day Competitive Generic Therapy Exclusivity". View Attachment
View stock analysis, news, and events for Glenmark Pharmaceuticals Limited